Nutra Pharma Completes FDA Submission For Nyloxin OTC And Nyloxin Rx - Over-the-Counter And Prescription Treatments For Chronic Pain

Main Category: Pain / Anesthetics
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 10 Dec 2009 - 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:4 stars

3.67 (6 votes)

Healthcare Prof:5 stars

5 (2 votes)


Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted the final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Nyloxin OTC, an over-the-counter treatment for moderate to severe (Stage 2) chronic pain, and Nyloxin Rx , a prescription treatment for severe (Stage 3) chronic pain.

"Completing the FDA registration for Nyloxin OTC and Nyloxin Rx is an important and required step towards introducing our Nyloxin-branded pain relievers throughout domestic and international markets," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma. "With the FDA registration now completed, we plan to immediately move forward with our launch of Nyloxin Rx here in the United States, while we finalize our international drug registrations in Canada, Europe and South America for both our prescription and over-the-counter formulations," he concluded.

The Company first introduced Nyloxin OTC in November as a treatment for moderate to severe (Stage 2) chronic pain. Nyloxin OTC is similar to the Company's recently launched pain reliever, Cobroxin , and will be available internationally as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additionally, the Company introduced Nyloxin Rx in October as a prescription treatment for severe (Stage 3) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one's ability to fully function.

Both Nyloxin OTC and Nyloxin Rx are produced by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm , and do not rely on the use of opioids or acetaminophen for their pain relieving action.

Source
Nutra Pharma Corp.

Article adapted by Medical News Today from original press release.
Visit our pain / anesthetics section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Nutra Pharma Corp.. "Nutra Pharma Completes FDA Submission For Nyloxin OTC And Nyloxin Rx - Over-the-Counter And Prescription Treatments For Chronic Pain." Medical News Today. MediLexicon, Intl., 10 Dec. 2009. Web.
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/173505.php>

APA
Nutra Pharma Corp.. (2009, December 10). "Nutra Pharma Completes FDA Submission For Nyloxin OTC And Nyloxin Rx - Over-the-Counter And Prescription Treatments For Chronic Pain." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/173505.php.

Please note: If no author information is provided, the source is cited instead.


Pain / Anesthetics

Opioids and Opioid-Induced Constipation (OIC)

Opioids are a class of drugs that are commonly prescribed for their analgesic, or pain-killing, properties. They include substances such as morphine, codeine, oxycodone, and methadone. Opioids may be more easily recognized by drug names such as Kadian... Read more...

Most Popular Articles



Follow Our Pain News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pain / Anesthetics Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »